By implementing paywalls, making exclusive content deals and incorporating ad tech, big media companies have reshaped what was once an entirely free and open ecosystem.
Rigor académico, oficio periodístico
Artículos sobre Intellectual property
Mostrando 21 - 40 de 136 artículos
Boosters and vaccinating children mean we’re relying on two pharmaceutical companies to supply Australia’s COVID vaccines. That needs to change.
Trademarking a shape of a product, or proving that a competitor is passing off their product as your own, is not easy. A high-profile settlement, though, is marketing gold.
The new variant is a warning: unless we take urgent action to correct global vaccine inequities, we risk the emergence of further variants, some of which may evade vaccines.
South Africa has a stringent pharmaceutical regulatory framework. But this framework is not backed by a strong implementation strategy.
The path to using old drugs for COVID is full of potholes. So why are we using the same old flawed methods when we actually know what works?
There’s a difference between owning property and owning the copyright in that property.
Potential benefits of human genome editing include new ways to diagnose, treat and prevent genetic disorders. But there’s a significant gap in regulation.
The Federal Court of Australia has made a world-first ruling in favour of granting a patent to an artificial intelligence. But what comes next?
Relying on donor funding means that the funder ultimately determines the health priorities. This is one reason why many programmes in Africa focus on a single disease such as HIV.
The pharmaceutical industry overall has been deeply opposed to waiving COVID-19 vaccine patents, but a historian of the industry explains that drug companies once opposed patents altogether.
Small and medium-sized businesses play an important role in economic growth and development but are hamstrung by their lack of adequate resources to market their goods and services.
Lowering the tax rates on profits from patents registered in Australia is unlikely to increase local research and development. But it will be a gift for multinationals.
Waiver talks might convince companies to focus on technology transfer and training, and let go of the plan to maximise patent-based revenues.
Much remains to be resolved before the waiver is translated into increased vaccine supply.
Despite some public virtue signalling, the Canadian government is not doing all it can to improve global access to COVID-19 vaccines. Canada has yet to announce its position on the WTO patent waiver.
The US has backed a proposal to waive intellectual property relating to COVID measures – but global efforts need to go beyond vaccine patents.
Various strategies are being pursued to boost worldwide vaccine coverage.
The change in the US position signals how clearly the success of every country in fighting the pandemic depends on vaccinating the whole world.
It’s not clear whether the TRIPS agreement is what’s getting in the way of vaccine supply, and waiving intellectual property rights may stifle future innovation.
Principales colaboradores
-
Reader in Intellectual Property Law, City, University of London
-
Professor in Intellectual Property and Innovation Law, Queensland University of Technology
-
Associate Professor in Public Health, La Trobe University
-
Professor of Law, University of Sydney
-
Associate Professor, School of Law, University of Canberra
-
Associate Vice President for Entrepreneurship and Innovation, Clemson University
-
ARC Future Fellow; Professor; Director, Intellectual Property Research Institute of Australia, The University of Melbourne
-
Senior Lecturer in Biochemistry and Cell Biology, University College Cork
-
Professor of Intellectual Property and Innovation Law; Director Centre for Intellectual Property Policy and Managament (CIPPM), Bournemouth University, Bournemouth University
-
Professor in International Relations / International Political Economy, UNSW Sydney
-
Senior Lecturer Above the Bar, University of Canterbury
-
Professor, University of Gondar
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
-
Director, Centre for Transformative Innovation, Swinburne University of Technology
-
Distinguished Professor, Arthur J. Gosnell Professor of Economics, & Interim Head, Department of Sustainability, Rochester Institute of Technology
